Dienstag, Jules L <br/><br/>
Benefits and risks of nucleoside analog therapy for hepatitis B.  [electronic resource] 

 -  Hepatology (Baltimore, Md.)  May 2009 
 - S112-21 p.  digital 
<br/><br/> Publication Type: Consensus Development Conference, NIH; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-3350 
<br/><br/><label>Standard No.: </label>10.1002/hep.22920  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Antiviral Agents--administration & dosage<br/>Hepatitis B virus--drug effects<br/>Hepatitis B, Chronic--drug therapy<br/>Humans<br/>Nucleosides--administration & dosage<br/>Risk Factors